Landmark Music-Dmd Phase 1b trial represents first-in-human gene therapy approach for DMD-associated heart failureBOSTON and Kansas City, Kan., July 15, 2025 Globe Newswire -- Medera Inc. Medera , a clinical-stage biopha
Why Is Keen Vision Acquisition Corporation (KVAC) Stock Down Today?
Updated Nov 22, 2026 8:06 AM ET ยท Prev Close $13.25
Session Regime & Catalyst Assessment
68% Signal ConvictionKeen Vision Acquisition Corporation Pulling Back 13.13% on 1.49x Relative Volume
Keen Vision Acquisition Corporation (KVAC) is pulling back 13.13% (-$1.74) to $11.51 on 1.49x average session volume. Relative to benchmarks, KVAC is lagging the S&P 500 by -9.49%.
Landmark Music-Dmd Phase 1b trial represents first-in-human gene therapy approach for DMD-associated heart failureBOSTON and Kansas City, Kan., July 15, 2025 Globe Newswire -- Medera Inc. Medera , a clinical-stage biopha
Market & Sector Relative Strength
KVAC lagging the S&P 500 by -9.49%Options Flow & Execution Desk
Recent KVAC Catalyst Headlines
Verified WireFirst-ever mini-Heart models will be created from hypoplastic left heart syndrome HLHS patient stem cells, enabling personalized insights into their causes and treatmentsPartnership aims to improve survival and quality o
Showcased 7 presentations at Isscr 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology.FDA-backed human-based screening
Results from Music-HfpEF Phase 1 2a clinical trial show favorable safety profile and early clinical benefits with Srd-002 gene therapy Boston, May 19, 2025 Globe Newswire -- Medera Inc. Medera , a clinical-stage biopharm
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $11.51 (session support) for directional breakout confirmation.
Retail & Crowd Sentiment
BearishA bullish StockTwits message suggests a potential price increase for $KVAC warrants, but no recent news articles were found to provide context.
About Keen Vision Acquisition Corporation
Get Instant KVAC Catalyst Alerts
Receive an email alert when KVAC triggers an unusual volume breakout, options sweep, or rating shift.
KVAC Session & Catalyst FAQ
Why is KVAC stock down today?
Keen Vision Acquisition Corporation (KVAC) is pulling back 13.13% (-$1.74) to $11.51 on 1.49x average session volume. Relative to benchmarks, KVAC is lagging the S&P 500 by -9.49%.
Is KVAC stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.49x relative volume (moderate participation). Our multi-factor model currently rates KVAC as HOLD. Review full valuation, quality, and timing signals on the KVAC Buy or Sell Decision Brief โ
What is KVAC's intrinsic value and expected trading range?
At $11.51, KVAC's modeled 1-to-3 session range is $10.88 โ $12.14, with a key inflection level at $11.51 (session support). Compare current price against multi-year cash flow projections in the KVAC Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.